Eli Lilly and Company (LLY) announced a settlement agreement with Totality Medispa that sold compounded products in the name of its popular tirzepatide drugs, Mounjaro and Zepbound. The medical spa coaxed customers into believing that its compounded tirzepatide products have undergone clinical tests and have been proven safe and effective.Eli Lilly’s Mounjaro was launched in mid-2022 for type II diabetes. Zepbound was launched in November 2023 for patients who were obese or overweight with weight-related co ...

Both of these businesses are finding traction in a pair of major markets.It's a truism in the stock market that winners tend to keep winning. For pharmaceutical companies, making good on that axiom requires a lot of hard work to develop new medicines, and to find ways of adding to established markets that are addressable by their existing drug portfolios.But the best competitors do it anyway, again and again. So let's examine a pair of today's leading drug businesses and see how they're building up their le ...

It's hard to bet against this high-flying stock.Excellent, magnificent, fantastic! All of these superlatives (and more) describe Eli Lilly's (LLY -1.50%) performance in recent years as it has delivered market-crushing returns and strong regulatory progress. Though the stock might peak eventually, we aren't there yet, as the pharmaceutical giant proved with its latest quarterly update. There remains substantial upside for Eli Lilly, and given its prospects, it's hard to pass up on the drugmaker.Strong financ ...

禮來（LLY） 更新報告 買入 2024年5月3日 替爾泊肽供不應求，公司調高 24年收入預期 但玉翠  24 年 Q1 EPS 同比增長 66%：24 年 Q1 收入同比+26%至 87.7 億美元，得 852-253219539 益於 Mounjaro（+218%至18.1億美元）、Zepbound、Verzenio（阿貝西 Tracy.dan@firstshanghai.com.hk 利 ，+40%至 10.5 億美元） 和 Jardiance（恩格列淨，+19%至 6.9 億美 元）的增長。毛利率同比+4.3 個百分點至 80.9%，研發費用同比+27%至 高小迪 25.2 億美元，研發費率同比+0.3 個百分點至 28.8%，另收購在研項目研 852-25321960 發 費用1.1億美元。銷售管理費用同比增長12%至19.5億美元，S&GA費 率同比下降 2.8 個百分點至 22.3%。綜上所述，公司 GAAP 淨利潤同比增 xiaodi.gao@firstshanghai.com.hk 長67%至22.4億美元，EPS同比增長66%至2.48美元，24年1季度公司 分紅12億美元。  各版塊 ...

The company's payout is far from the only reason investors like the stock these days, but it certainly helps.The largest pharmaceutical company in the world by market cap, Eli Lilly (LLY 4.31%), is continuing to share some of its profits with shareholders. The company has kept its quarterly dividend payments flowing, and declared a new distribution on Monday. Investors like getting cash from their companies, and this upcoming payment is generous compared to what it was only a few months ago.Fresh dividend d ...

INDIANAPOLIS, May 6, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on June 10, 2024, to shareholders of record at the close of business on May 16, 2024. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and tod ...

Did you analyze how Eli Lilly (LLY) fared in its international operations for the quarter ending March 2024? Given the widespread global presence of this drugmaker, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importa ...

Key PointsEli Lilly reported a Q1 2024 EPS rise of 66%, beating analyst expectations by 11 cents, but slightly missed revenue expectations, coming in at $8.77 billion, falling short of $8.94 billion consensus estimates.Eli Lilly raised full-year 2024 EPS and full-year revenue guidance by $2 billion.Eli Lilly broke ground on its new $2.5 billion manufacturing facility in Germany, and its Concord, North Carolina facility expects to produce Wegovy shipments by year's end.5 stocks we like better than Eli Lilly ...

The biggest healthcare company in the world could grow much larger over the next decade.Shares of Eli Lilly and Company (LLY -0.56%) have soared nearly 35% so far in 2024 and are only a few points away from doubling over the last 12 months. The company reigns as the biggest drugmaker in the world based on market cap. It's also the largest company in the entire healthcare sector. But has Lilly peaked? I don't think so. Here's why Lilly stock remains a screaming buy.1. Tremendous growth ahead for Mounjaro and ...

Eli Lilly and Company (LLY) posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.The stock jumped 6% in response to the earnings beat. Investors seeking to tap the opportune moment could bet on ETFs having the largest exposure to the drugmaker. These include iShares U.S. Pharmaceuticals ETF (IHE) , Horizon Kinetics ...